Multifocal serous retinopathy with pemigatinib therapy for metastatic colon adenocarcinoma.

Background: Pemigatinib is an inhibitor of the fibroblast growth factor receptor (FGFR), recently approved for the treatment of cholangiocarcinoma. FGFR retinopathy is a newly recognized entity, with only two other FGFR inhibitors reported to cause serous retinopathy. Herein, we describe the first published report of a multifocal serous retinopathy secondary to pemigatinib.

Demographic trends of open globe injuries in a large inpatient sample.

Purpose: To evaluate demographic trends of open globe injuries (OGIs) using a large dataset representative of United States population.

Methods: Retrospective cross-sectional observational study using the National Inpatient Sample (NIS) database from 2002 to 2013. Only patients with a primary admitting diagnosis of OGI were included.

Predictive factors of enucleation after open globe injuries.

Background: Trauma is the leading cause of enucleations in the USA. Current information regarding open globe injuries (OGI) is based mainly on data from individual tertiary care centers across the country which might skew the findings towards the population served by these level-one trauma centers. The aim of this study is to evaluate the demographics, characteristics, and risk factors of traumatic enucleations in a large data sample.